Open Payments

RANY ABURASHED

Type
Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
Where
Dearborn, MI
NPI
1790909711
Received
$450,238 in 458 records, 2019 to 2025 ($440,418 general, $9,819 research)
As principal investigator
$1,462,495 of research payments to others in 408 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment4$102
2024General payment3$753
2023General payment8$48,798
2022General payment21$24,238
2022Research payment4$5,041
2021General payment71$89,353
2021Research payment2$1,567
2020General payment89$70,330
2020Research payment3$677
2019General payment239$206,842
2019Research payment14$2,534

By company

CompanyRecordsAmountYears
GENZYME CORPORATION108$115,0032019–2022
Biogen, Inc.72$59,0642019–2025
Genentech USA, Inc.47$53,7932019–2025
Novartis Pharmaceuticals Corporation81$52,6102019–2022
Medtronic, Inc.1$48,1672023
SANOFI-AVENTIS U.S. LLC13$41,2732019–2022
EMD Serono, Inc.39$28,7362019–2022
Celgene Corporation23$26,6522019–2025
E.R. Squibb & Sons, L.L.C.6$8,2292020–2021
F. Hoffmann-La Roche AG1$6,0002021
Mallinckrodt Hospital Products Inc.1$3,5752020
Janssen Pharmaceuticals, Inc2$2,6252021
Genentech, Inc.1$1,2002022
TG Therapeutics, Inc.3$9042022–2023
Intuitive Surgical, Inc.2$7282024
ABBVIE INC.9$6572019–2022
Grifols USA, LLC7$1832019
Allergan, Inc.10$1572019–2020
Bard Peripheral Vascular, Inc.1$992020
Teva Pharmaceuticals USA, Inc.5$722019–2020
Amgen Inc.3$602019
UCB, Inc.3$572019
Acorda Therapeutics, Inc2$422019
Alexion Pharmaceuticals, Inc.2$402019
ACADIA Pharmaceuticals Inc2$392019
Supernus Pharmaceuticals, Inc.2$392019
Nevro Corp.1$342023
Avanir Pharmaceuticals, Inc.2$302019
Alnylam Pharmaceuticals Inc.1$262023
CATALYST PHARMACEUTICALS, INC.1$232020
Lilly USA, LLC2$222019
SCILEX PHARMACEUTICALS INC.1$202023
KYOWA KIRIN, INC.1$172020
HARMONY BIOSCIENCES LLC1$172022
Neurocrine BioSciences, Inc.1$162020
Eisai Inc.1$132020

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v99$251,803
Consulting Fee25$93,801
Acquisitions1$48,167
Travel and Lodging70$37,729
Research payment23$9,819
Food and Beverage238$8,784
Education2$131

Records

DateCompanyAmountNatureFormProductStudyYear
2025-04-24Genentech USA, Inc.$28Food and BeverageIn-kind items and servicesOcrevus Zunovo Biological, Immunology2025
2025-04-14Biogen, Inc.$28Food and BeverageIn-kind items and servicesTYSABRI Biological, Neurology2025
2025-01-30Celgene Corporation$29Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2025
2025-01-23Celgene Corporation$16Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2025
2024-11-13Intuitive Surgical, Inc.$709Travel and LodgingIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2024
2024-11-13Intuitive Surgical, Inc.$19Travel and LodgingIn-kind items and servicesDa Vinci Surgical System Device, SURGERY2024
2024-06-03Genentech USA, Inc.$24Food and BeverageIn-kind items and servicesOcrevus Biological, Immunology2024
2023-11-26SCILEX PHARMACEUTICALS INC.$20Food and BeverageIn-kind items and servicesZTLido Drug, Analgesic2023
2023-11-20Genentech USA, Inc.$21Food and BeverageIn-kind items and servicesEnspryng Biological, Immunology2023
2023-07-18Alnylam Pharmaceuticals Inc.$26Food and BeverageIn-kind items and servicesAMVUTTRA Drug, Genetic Disease2023
2023-06-13Genentech USA, Inc.$22Food and BeverageIn-kind items and servicesOcrevus Biological, Immunology2023
2023-05-08TG Therapeutics, Inc.$104Food and BeverageIn-kind items and servicesBRIUMVI Drug, Immunology2023
2023-03-29Medtronic, Inc.$48,167AcquisitionsCash or cash equivalent2023
2023-03-20TG Therapeutics, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBRIUMVI Drug, Immunology2023
2023-01-30Nevro Corp.$34Food and BeverageIn-kind items and servicesSenza Device, Spinal Cord Stimulator2023
2022-11-30Novartis Pharmaceuticals Corporation$2,683Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-11-15ABBVIE INC.$19Food and BeverageIn-kind items and servicesDUOPA Drug, NEUROSCIENCE2022
2022-11-10GENZYME CORPORATION$1,978Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-10-26Novartis Pharmaceuticals Corporation$983Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-09-01GENZYME CORPORATION$1,130Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-07-28GENZYME CORPORATION$1,978Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-07-15HARMONY BIOSCIENCES LLC$17Food and BeverageCash or cash equivalentWakix Drug, Neurological Disorders2022
2022-07-01EMD Serono, Inc.$3,080Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-06-14EMD Serono, Inc.$3,080Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMavenclad Drug, Neurology2022
2022-06-14EMD Serono, Inc.$3,080Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-06-10EMD Serono, Inc.$275Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMavenclad Drug, Neurology2022
2022-06-09EMD Serono, Inc.$1,473Travel and LodgingCash or cash equivalent2022
2022-06-09EMD Serono, Inc.$646Travel and LodgingCash or cash equivalent2022
2022-06-09EMD Serono, Inc.$336Travel and LodgingCash or cash equivalent2022
2022-06-09EMD Serono, Inc.$100Food and BeverageCash or cash equivalentMavenclad Drug, Neurology2022
2022-05-18Novartis Pharmaceuticals Corporation$392Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-05-13GENZYME CORPORATION$2,628Consulting FeeCash or cash equivalent2022
2022-05-12SANOFI-AVENTIS U.S. LLC$125Food and BeverageIn-kind items and servicesAUBAGIO Drug, Neurology2022
2022-05-10TG Therapeutics, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2022
2022-03-10Biogen, Inc.$1,836Consulting FeeCash or cash equivalentTYSABRI Biological, Neurology2022
2022-03-10Genentech, Inc.$1,200Consulting FeeCash or cash equivalent Drug2022
2022-02-24Novartis Pharmaceuticals Corporation$983Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH2022
2022-02-23EMD Serono, Inc.$275Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMavenclad Drug, Neurology2022
2022-01-19Novartis Pharmaceuticals Corporation$14Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2022
2022-01-06Biogen, Inc.$565Consulting FeeCash or cash equivalentTYSABRI Biological, Neurology2022
2021-12-07Novartis Pharmaceuticals Corporation$4Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-11-19EMD Serono, Inc.$3,080Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMavenclad Drug, Neurology2021
2021-11-18Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-11-11SANOFI-AVENTIS U.S. LLC$48Food and BeverageIn-kind items and servicesAUBAGIO Drug, Neurology2021
2021-11-10Biogen, Inc.$30Food and BeverageIn-kind items and servicesTYSABRI Biological, NEUROLOGY2021
2021-11-09E.R. Squibb & Sons, L.L.C.$4,030Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-11-09Novartis Pharmaceuticals Corporation$317Research paymentIn-kind items and servicesARZERRA Drug, HEMATOLOGYPUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH2021
2021-11-05GENZYME CORPORATION$4,746Consulting FeeCash or cash equivalentAUBAGIO Drug, Neurology2021
2021-11-02E.R. Squibb & Sons, L.L.C.$4,030Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-11-01Biogen, Inc.$1,695Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYSABRI Biological, NEUROLOGY2021
2021-10-29GENZYME CORPORATION$2,184Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-10-28GENZYME CORPORATION$1,911Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUBAGIO Drug, Neurology2021
2021-10-25Biogen, Inc.$4,520Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVUMERITY Drug, NEUROLOGY2021
2021-10-25Biogen, Inc.$50Food and BeverageCash or cash equivalentVUMERITY Drug, NEUROLOGY2021
2021-10-22GENZYME CORPORATION$4,095Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUBAGIO Drug, Neurology2021
2021-10-22GENZYME CORPORATION$16Food and BeverageIn-kind items and servicesAUBAGIO Drug, Neurology2021
2021-10-21E.R. Squibb & Sons, L.L.C.$81Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-10-20Novartis Pharmaceuticals Corporation$17Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-10-14E.R. Squibb & Sons, L.L.C.$44Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-10-11Genentech USA, Inc.$4,800Consulting FeeCash or cash equivalentOCREVUS Biological, Immunology2021
2021-10-08Genentech USA, Inc.$4,040Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOCREVUS Biological, Immunology2021
2021-10-08Genentech USA, Inc.$2,530Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOCREVUS Biological, Immunology2021
2021-10-08Genentech USA, Inc.$39Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2021
2021-10-08Genentech USA, Inc.$22Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2021
2021-10-08Novartis Pharmaceuticals Corporation$11Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-10-07Genentech USA, Inc.$4,040Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-10-07Genentech USA, Inc.$1,921Travel and LodgingCash or cash equivalent2021
2021-10-07Genentech USA, Inc.$864Travel and LodgingCash or cash equivalent2021
2021-10-07Genentech USA, Inc.$110Food and BeverageIn-kind items and services2021
2021-10-06Novartis Pharmaceuticals Corporation$1,064Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentKESIMPTA Drug, NEUROSCIENCE2021
2021-09-30Janssen Pharmaceuticals, Inc$45Food and BeverageIn-kind items and servicesPonvory Drug, Neuroscience2021
2021-09-23Janssen Pharmaceuticals, Inc$2,580Consulting FeeCash or cash equivalent2021
2021-09-23Genentech USA, Inc.$112Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2021
2021-09-23Biogen, Inc.$4Food and BeverageIn-kind items and servicesVUMERITY Drug, NEUROLOGY2021
2021-09-22Biogen, Inc.$1,695Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYSABRI Biological, NEUROLOGY2021
2021-09-20Novartis Pharmaceuticals Corporation$10Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-09-16Genentech USA, Inc.$4,040Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOCREVUS Biological, Immunology2021
2021-09-16Genentech USA, Inc.$47Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2021
2021-09-13Biogen, Inc.$4,520Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVUMERITY Drug, NEUROLOGY2021
2021-09-13Biogen, Inc.$80Food and BeverageCash or cash equivalentVUMERITY Drug, NEUROLOGY2021
2021-09-02Genentech USA, Inc.$2,530Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOCREVUS Biological, Immunology2021
2021-09-02Genentech USA, Inc.$21Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2021
2021-08-20Genentech USA, Inc.$1,010Consulting FeeCash or cash equivalentOCREVUS Biological, Immunology2021
2021-08-13EMD Serono, Inc.$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-08-10Genentech USA, Inc.$22Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2021
2021-08-05Celgene Corporation$26Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-07-22Novartis Pharmaceuticals Corporation$2,596Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentKESIMPTA Drug, NEUROSCIENCE2021
2021-06-24GENZYME CORPORATION$1,250Research paymentIn-kind items and servicesLEMTRADA Biological, NeurologyA Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly S2021
2021-06-23Novartis Pharmaceuticals Corporation$14Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-06-22Novartis Pharmaceuticals Corporation$5Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-06-17Biogen, Inc.$1,695Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-06-14EMD Serono, Inc.$1,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2021
2021-06-14Novartis Pharmaceuticals Corporation$7Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-05-30Novartis Pharmaceuticals Corporation$5Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-05-11Novartis Pharmaceuticals Corporation$14Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-05-10Biogen, Inc.$8Food and BeverageIn-kind items and servicesVUMERITY Drug, NEUROLOGY2021
2021-04-27EMD Serono, Inc.$275Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMavenclad Drug, Neurology2021
2021-04-20Novartis Pharmaceuticals Corporation$7Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-04-06Celgene Corporation$1,550Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-04-01Biogen, Inc.$3,013Consulting FeeCash or cash equivalentTYSABRI Biological, NEUROLOGY2021
2021-03-28Celgene Corporation$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2021
2021-03-23EMD Serono, Inc.$1,540Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMavenclad Drug, Neurology2021
2021-03-22Novartis Pharmaceuticals Corporation$16Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-03-22Biogen, Inc.$9Food and BeverageIn-kind items and servicesTYSABRI Biological, NEUROLOGY2021
2021-03-16Novartis Pharmaceuticals Corporation$1,064Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentKESIMPTA Drug, NEUROSCIENCE2021
2021-03-15F. Hoffmann-La Roche AG$6,000Consulting FeeCash or cash equivalentTamiflu Drug, Virology & Specialty Care2021
2021-03-11Genentech USA, Inc.$2,185Consulting FeeCash or cash equivalentOCREVUS Biological, Immunology2021
2021-03-08Novartis Pharmaceuticals Corporation$9Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-03-02Novartis Pharmaceuticals Corporation$10Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-02-22Novartis Pharmaceuticals Corporation$6Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-02-11Novartis Pharmaceuticals Corporation$6Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-02-04Novartis Pharmaceuticals Corporation$15Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2021
2021-01-28Biogen, Inc.$4Food and BeverageIn-kind items and servicesTYSABRI Biological, NEUROLOGY2021
2020-12-17Celgene Corporation$2,170Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-12-02Novartis Pharmaceuticals Corporation$13Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2020
2020-11-07Novartis Pharmaceuticals Corporation$14Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2020
2020-11-05Novartis Pharmaceuticals Corporation$1,064Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentKESIMPTA Drug, NEUROSCIENCE2020
2020-10-15Genentech USA, Inc.$2,185Consulting FeeCash or cash equivalentOCREVUS Biological, Immunology2020
2020-10-08Biogen, Inc.$2,625Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTYSABRI Biological, NEUROLOGY2020
2020-09-25Novartis Pharmaceuticals Corporation$9Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2020
2020-09-24Novartis Pharmaceuticals Corporation$8Food and BeverageIn-kind items and servicesKESIMPTA Drug, NEUROSCIENCE2020
2020-08-27Novartis Pharmaceuticals Corporation$600Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentKESIMPTA Drug, NEUROSCIENCE2020
2020-08-24Teva Pharmaceuticals USA, Inc.$15Food and BeverageIn-kind items and servicesAJOVY Biological, Central Nervous System2020
2020-08-11E.R. Squibb & Sons, L.L.C.$13Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-08-03GENZYME CORPORATION$574Research paymentIn-kind items and servicesLEMTRADA Biological, NeurologyA long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS0342020
2020-07-31GENZYME CORPORATION$1,298Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUBAGIO Drug, Neurology2020
2020-07-17GENZYME CORPORATION$1,038Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUBAGIO Drug, Neurology2020
2020-07-17GENZYME CORPORATION$1,038Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUBAGIO Drug, Neurology2020
2020-07-16Celgene Corporation$2,170Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-07-16GENZYME CORPORATION$1,038Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUBAGIO Drug, Neurology2020
2020-07-13SANOFI-AVENTIS U.S. LLC$21Food and BeverageIn-kind items and servicesAUBAGIO Drug, Neurology2020
2020-07-07Genentech USA, Inc.$14Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2020
2020-06-30Celgene Corporation$1,440Consulting FeeCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-06-27Genentech USA, Inc.$4,120Consulting FeeCash or cash equivalentOCREVUS Biological, Immunology2020
2020-06-19GENZYME CORPORATION$4,585Consulting FeeCash or cash equivalentAUBAGIO Drug, Neurology2020
2020-06-18Celgene Corporation$2,170Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-06-15E.R. Squibb & Sons, L.L.C.$28Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-06-05Novartis Pharmaceuticals Corporation$2,128Consulting FeeCash or cash equivalentMAYZENT Drug, NEUROSCIENCE2020
2020-05-26EMD Serono, Inc.$24Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-05-16Genentech USA, Inc.$2,439Consulting FeeCash or cash equivalentOCREVUS Biological, Immunology2020
2020-05-05Celgene Corporation$620Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-04-16Mallinckrodt Hospital Products Inc.$3,575Consulting FeeCash or cash equivalentACTHAR Biological, IMMUNOLOGY2020
2020-03-31GENZYME CORPORATION$74Research paymentIn-kind items and servicesLEMTRADA Biological, NeurologyA long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS0342020
2020-03-31GENZYME CORPORATION$28Research paymentIn-kind items and servicesLEMTRADA Biological, NeurologyAn Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab2020
2020-03-25Genentech USA, Inc.$506Travel and LodgingCash or cash equivalentOCREVUS Biological, Immunology2020
2020-03-12Novartis Pharmaceuticals Corporation$24Food and BeverageIn-kind items and servicesAIMOVIG Biological, NEUROSCIENCE2020
2020-03-10KYOWA KIRIN, INC.$17Food and BeverageIn-kind items and servicesNOURIANZ Drug, ADENOSINE A2A RECEPTORS2020
2020-03-08Allergan, Inc.$13Food and BeverageIn-kind items and servicesBOTOX Biological, HYPERHYDROSIS2020
2020-03-04Novartis Pharmaceuticals Corporation$7Food and BeverageIn-kind items and servicesMAYZENT Drug, NEUROSCIENCE2020
2020-03-02Novartis Pharmaceuticals Corporation$13Food and BeverageIn-kind items and servicesMAYZENT Drug, NEUROSCIENCE2020
2020-02-28EMD Serono, Inc.$3,960Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMavenclad Drug, Neurology2020
2020-02-27Allergan, Inc.$16Food and BeverageIn-kind items and servicesBOTOX Biological, HYPERHYDROSIS2020
2020-02-25Genentech USA, Inc.$19Food and BeverageIn-kind items and servicesOCREVUS Biological, Immunology2020
2020-02-24Novartis Pharmaceuticals Corporation$10Food and BeverageIn-kind items and servicesMAYZENT Drug, NEUROSCIENCE2020
2020-02-22Celgene Corporation$4,650Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-22Celgene Corporation$541Travel and LodgingCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-22Celgene Corporation$520Travel and LodgingCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-22Celgene Corporation$60Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-22Celgene Corporation$60Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-22Celgene Corporation$50Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-22Celgene Corporation$29Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-22Celgene Corporation$8Food and BeverageCash or cash equivalentZEPOSIA Drug, Neuroscience2020
2020-02-20GENZYME CORPORATION$2,465Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentLEMTRADA Biological, Neurology2020
2020-02-20GENZYME CORPORATION$124Food and BeverageIn-kind items and servicesLEMTRADA Biological, Neurology2020
2020-02-20Bard Peripheral Vascular, Inc.$99Food and BeverageIn-kind items and services2020
2020-02-20GENZYME CORPORATION$18Food and BeverageIn-kind items and servicesLEMTRADA Biological, Neurology2020
2020-02-17GENZYME CORPORATION$17Food and BeverageIn-kind items and servicesLEMTRADA Biological, Neurology2020
2020-02-13Allergan, Inc.$13Food and BeverageIn-kind items and servicesUBRELVY Drug, NEUROSCIENCE2020
2020-02-08GENZYME CORPORATION$9,968Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentAUBAGIO Drug, Neurology2020
2020-02-08GENZYME CORPORATION$330Travel and LodgingIn-kind items and servicesAUBAGIO Drug, Neurology2020
2020-02-08GENZYME CORPORATION$214Travel and LodgingIn-kind items and servicesAUBAGIO Drug, Neurology2020
2020-02-08GENZYME CORPORATION$99Travel and LodgingIn-kind items and servicesAUBAGIO Drug, Neurology2020
2020-02-08GENZYME CORPORATION$60Food and BeverageIn-kind items and servicesAUBAGIO Drug, Neurology2020
2020-02-08GENZYME CORPORATION$51Food and BeverageIn-kind items and servicesAUBAGIO Drug, Neurology2020
2020-02-06Teva Pharmaceuticals USA, Inc.$15Food and BeverageIn-kind items and servicesAJOVY Biological, Central Nervous System2020
2020-02-03Biogen, Inc.$23Food and BeverageIn-kind items and servicesAVONEX Biological, NEUROLOGY2020
2020-01-30Novartis Pharmaceuticals Corporation$22Food and BeverageIn-kind items and servicesAIMOVIG Biological, NEUROSCIENCE2020
2020-01-28Eisai Inc.$13Food and BeverageCash or cash equivalentFycompa Drug, Neurology2020
2020-01-25EMD Serono, Inc.$743Travel and LodgingIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-25EMD Serono, Inc.$52Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-25EMD Serono, Inc.$31Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-25EMD Serono, Inc.$23Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-25EMD Serono, Inc.$15Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-25EMD Serono, Inc.$12Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-25EMD Serono, Inc.$12Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-25EMD Serono, Inc.$3Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-24EMD Serono, Inc.$292Travel and LodgingIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-24EMD Serono, Inc.$82Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-24EMD Serono, Inc.$7Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-24EMD Serono, Inc.$2Food and BeverageIn-kind items and servicesMavenclad Drug, Neurology2020
2020-01-23CATALYST PHARMACEUTICALS, INC.$23Food and BeverageIn-kind items and servicesFIRDAPSE Drug, NEUROLOGY2020
2020-01-18GENZYME CORPORATION$20Food and BeverageIn-kind items and services2020
2020-01-16Neurocrine BioSciences, Inc.$16Food and BeverageIn-kind items and servicesINGREZZA Drug, NEUROLOGY2020
2020-01-14Novartis Pharmaceuticals Corporation$12Food and BeverageIn-kind items and servicesMAYZENT Drug, NEUROSCIENCE2020
2020-01-13ABBVIE INC.$20Food and BeverageIn-kind items and servicesDUOPA Drug, NEUROSCIENCE2020
2020-01-11Biogen, Inc.$7,088Consulting FeeCash or cash equivalentTYSABRI Biological, NEUROLOGY2020
2020-01-11Biogen, Inc.$432Travel and LodgingCash or cash equivalentTYSABRI Biological, NEUROLOGY2020
2020-01-11Biogen, Inc.$196Travel and LodgingCash or cash equivalentTYSABRI Biological, NEUROLOGY2020
2020-01-11Biogen, Inc.$117Food and BeverageIn-kind items and servicesTYSABRI Biological, NEUROLOGY2020
2020-01-11Biogen, Inc.$89Food and BeverageIn-kind items and servicesTYSABRI Biological, NEUROLOGY2020

The latest 200 records of 458.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-22GENZYME CORPORATIONMEMORIAL HEALTHCARE$8,743A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-12-17Janssen Research & Development, LLCInsight Rsrch Inst Inc.$2,122A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-11-24GENZYME CORPORATIONMEMORIAL HEALTHCARE$83A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-10-14GENZYME CORPORATIONMEMORIAL HEALTHCARE$498A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-10-14GENZYME CORPORATIONMEMORIAL HEALTHCARE$55A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-10-06GENZYME CORPORATIONMEMORIAL HEALTHCARE$8,577A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-09-19Janssen Research & Development, LLCInsight Rsrch Inst Inc.$1,286A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-09-15GENZYME CORPORATIONMEMORIAL HEALTHCARE$83A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-09-15GENZYME CORPORATIONMEMORIAL HEALTHCARE$118A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-07-28Janssen Research & Development, LLCInsight Rsrch Inst Inc.$6A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-07-02GENZYME CORPORATIONMEMORIAL HEALTHCARE$332A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-07-02GENZYME CORPORATIONMEMORIAL HEALTHCARE$1,697A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-05-27GENZYME CORPORATIONMEMORIAL HEALTHCARE$5A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-05-27GENZYME CORPORATIONMEMORIAL HEALTHCARE$249A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-05-16Janssen Research & Development, LLCInsight Rsrch Inst Inc.$1,908A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-04-28GENZYME CORPORATIONMEMORIAL HEALTHCARE$1,876A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-04-07GENZYME CORPORATIONMEMORIAL HEALTHCARE$1,000A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-04-07GENZYME CORPORATIONMEMORIAL HEALTHCARE$1,378A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-04-07GENZYME CORPORATIONMEMORIAL HEALTHCARE$100A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-04-07GENZYME CORPORATIONMEMORIAL HEALTHCARE$1,100A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-02-19Janssen Research & Development, LLCInsight Rsrch Inst Inc.$1,908A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-02-18GENZYME CORPORATIONMEMORIAL HEALTHCARE$415A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-02-18GENZYME CORPORATIONMEMORIAL HEALTHCARE$799A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-01-06GENZYME CORPORATIONMEMORIAL HEALTHCARE$1,707A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2025
2025-01-06GENZYME CORPORATIONMEMORIAL HEALTHCARE$606A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2025
2024-12-03GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$29,743A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-12-03GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,863A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-11-18Janssen Research & Development, LLCInsight Rsrch Inst Inc.$2,12270033093STR30012024
2024-10-21GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,863A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-10-21GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$8,811A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-10-15GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$407A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-10-02GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,606A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-10-02GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$249A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-09-13Janssen Research & Development, LLCInsight Rsrch Inst Inc.$83070033093STR30012024
2024-09-04GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,000A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-08-23Janssen Research & Development, LLCInsight Rsrch Inst Inc.$2,72970033093STR30012024
2024-07-29GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$3,138A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-07-24Janssen Research & Development, LLCInsight Rsrch Inst Inc.$41570033093STR30012024
2024-07-22GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$125A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-07-22GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$415A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-06-19Janssen Research & Development, LLCBiomdcl Rsrch Allnce Of New York Llc$3,93370033093STR30012024
2024-06-10GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$230A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-05-28GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$415A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-05-22Janssen Research & Development, LLCBiomdcl Rsrch Allnce Of New York Llc$1,34970033093STR30012024
2024-04-22GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$166A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-04-15GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$50A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-04-08Janssen Research & Development, LLCBiomdcl Rsrch Allnce Of New York Llc$4,24970033093STR30012024
2024-03-18GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,415A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-03-04GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$249A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-02-21Janssen Research & Development, LLCInsight Rsrch Inst Inc.$2,81770033093STR30012024
2024-02-20GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$50A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-02-12GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,863A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-02-05GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$168A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-02-05GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,863A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-01-31Novartis Pharmaceuticals CorporationINSIGHT HOSPITAL AND MEDICAL CENTER$1,263A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus2024
2024-01-22GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$249A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-01-16GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$83A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-01-16GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$75A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2024-01-03GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$83A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2024
2024-01-03GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,863A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2024
2023-12-13Janssen Research & Development, LLCInsight Rsrch Inst Inc.$1,43370033093STR30012023
2023-12-04GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$9,014A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-11-22Janssen Research & Development, LLCInsight Rsrch Inst Inc.$5,19370033093STR30012023
2023-11-20GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$143A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-11-14GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$500A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre2023
2023-11-14GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$415A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre2023
2023-11-14GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$83A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-11-14GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$8,811A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-11-06GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$293A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-10-30GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$11,124A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-10-30GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,500A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-10-16GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$348A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-10-10GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$205A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-10-10GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$83A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-09-20Janssen Research & Development, LLCInsight Rsrch Inst Inc.$1,43370033093STR30012023
2023-09-18GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$75A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-09-11GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$166A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-09-05GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,863A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-08-28GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,650A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-08-28GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,500A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-08-23Janssen Research & Development, LLCInsight Rsrch Inst Inc.$5,52170033093STR30012023
2023-08-21GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$249A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-08-07GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$249A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-08-02GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$3,726A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-08-02GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,863A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-07-17GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,494A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-07-17GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$286A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-07-17GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$83A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-07-10GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,100A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-07-10GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$308A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-07-10GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$83A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-07-05GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$143A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-07-05GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$332A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-07-05GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$1,100A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-05-25GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$5,977A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-05-25GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$581A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima2023
2023-05-24Janssen Research & Development, LLCInsight Rsrch Inst Inc.$5,15870033093STR30012023
2023-05-15GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$830A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip2023
2023-05-15GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$249A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre2023
2023-05-15GENZYME CORPORATIONMemorial Hospital Memorial Healthcare Memorial Medica Associates$3,397A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre2023

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDearborn city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Dearborn, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Dearborn, MI
County
Wayne County, MI
State
Michigan
Population B01003107,4231,772,25910,077,761
Population, 2020 census P1109,9761,793,56110,077,331
Median age B0100233.337.940.2
Under 18 B0100128.7%23.6%21.2%
65 and over B0100113.7%16.6%18.6%
Households B1100136,695700,5914,076,369
Foreign born B0500230.3%10.3%7.2%
Median household income B19013$65,324$60,539$72,875
Median family income B19113$74,152$79,522$93,357
Per capita income B19301$30,588$34,906$40,735
Poverty rate B1700124.3%20.8%13.2%
Unemployment rate B230256.6%8.7%5.7%
Civilian labor force B2302545,028828,8385,018,449
Mean commute (minutes) B0801321.724.724.2
Bachelor's degree or higher B1500334.6%27.6%32.4%
Housing units B2500139,394801,0834,622,236
Owner-occupied B2500368.4%64.8%73.2%
Renters B2500331.6%35.2%26.8%
Median home value B25077$218,800$178,500$231,600
Median gross rent B25064$1,327$1,132$1,129
White, not Hispanic B0300287.3%47.9%72.4%
Black B030023.6%36.6%13.1%
Hispanic or Latino B030022.7%6.9%5.9%
Asian B030021.8%3.7%3.4%
American Indian and Alaska Native B030020.1%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Dearborn, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.